Research programme: serotonin 1A/dopamine agonists - BayerAlternative Names: Serotonin 1A/dopamine agonists research programme - Bayer
Latest Information Update: 26 Mar 2010
At a glance
- Originator Bayer
- Mechanism of Action Dopamine receptor agonists; Serotonin 1A receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 26 Mar 2010 Discontinued - Preclinical for Parkinson's disease in Germany (unspecified route)
- 19 Mar 2001 Preclinical development for Parkinson's disease in Germany (Unknown route)